Research programme: oral IL-17 Inhibitors - Sanofi
Latest Information Update: 28 Sep 2024
Price :
$50 *
At a glance
- Originator C4X Discovery
- Class Antipsoriatics; Small molecules
- Mechanism of Action Interleukin 17 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Psoriasis